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Introduction
Familial amyloid polyneuropathy (FAP) is one 
form of hereditary amyloidosis, initially showing 
polyneuropathy and autonomic dysfunction but 
later involving many visceral organs. This disorder 
was first clearly described in Portugal in 1952.1 
The understanding of FAP, including the molecular 
pathogenesis and diagnostic technology, has greatly 
progressed. There are three main types of FAP, 
defined according to the precursor protein of amyloid: 
transthyretin (TTR), apolipoprotein A-1, and gelsolin.2 
TTR is a main constituent of amyloid deposits in FAP,3 
and the complete amino acid sequence of TTR-related 
amyloid fibril protein was reported in 1983, showing 
one amino acid substitution (a valine-to-methionine 
change at position 30).4 With use of DNA analysis or 
protein chemistry techniques, more than 80 mutations 
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There	are	three	precursor	proteins	of	amyloid	inducing	familial	amyloid	polyneuropathy	(FAP):	transthyretin	(TTR),	
Apolipoprotein	A-1,	and	Gelsolin.	Abnormal	TTR	expression	is	most	frequently	discovered	in	FAP	and	the	genotypes	
are	correlated	with	clinical	features.	Since	the	substitution	of	methionine	for	valine	at	position	30	is	most	common	gene	
mutation,	TTR	type	FAP	is	divided	into	Val30Met	type	FAP	and	non-Val30Met	type	FAP.	Asp38Ala	mutation	found	in	
non-Val30Met	type	FAP	usually	accompanied	the	autonomic	symptoms	and	only	reported	in	male	persons	in	Korea.	We	
reported	the	clinical	characteristics	and	disease	progression	of	first	Korean	female	person	with	Asp38Ala	mutation	who	
didn’t	show	autonomic	symptoms.
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have been identified as causative gene abnormality in 
TTR type FAP. TTR type FAP is classified into Val30Met 
type FAP and non-Val30Met type FAP because the 
substitution of methionine for valine at position 30 
(Val30Met) is the most common and showing clinical 
similarities.5,6 Contrarily, non-Val30Met type FAP is less 
common and its clinical features are various according 
to the type of genetic mutations.7 It has been reported 
that various genotypes, such as Ala25Tyr and Asp18Gly, 
are associated with specific phenotypes. However, 
phenotype of Asp38Ala mutation has been reported 
mainly in male patients and even never in Korean 
female patients.
We report a first female case of non-Val30Met type 
FAP with Asp38Ala mutation in Korea and describe 
her detailed clinical features, not accompanied with 
autonomic symptoms. 
Case Report
A 57-year-old female, who was diagnosed with 
hypertrophic cardiomyopathy (HCMP) 2 years ago, 
underwent sustained ventricular tachycardia without 
improvement by cardioversion, and admitted to 
cardiology department. Fabry disease was suspicious 
on cardiac echo and magnetic resonance imaging, but 
gene study for Fabry disease was negative. She was 
diagnosed with cardiac amyloidosis by muscle biopsy 
(Fig. 1) and discharged after insertion of implantable 
cardioverter defibrillator (ICD). 
After discharge, she was consulted to rehabilitation 
department to evaluate her tingling sensation and 
sensory impairments in both arms and legs since 3 
years ago. Tingling sensation started with discomfort 
in the feet and sensory loss has progressed above both 
ankle 6 months after onset. Tingling sensations and 
sensory loss gradually extended to the knees and both 
upper extremities started from both hands. She felt 
tingling sensations and sensory loss at bilateral 1st to 3rd 
fingers. She was diagnosed with bilateral carpal tunnel 
syndrome based on electrodiagnostic examination, 
but did not improve after operation about 2 years ago. 
She had no autonomic dysfunction such as orthostatic 
hypotension, constipation and diarrhea.
On her family history, her mother died from cardiac 
arrhythmia, her brother diagnosed myocardial hyper-
trophy and her sister suffered from tingling sensation 
in both hands. On physical examination, muscular 
strengths of the ankle plantar flexor were reduced 
to the fair grade and sensory examination was also 
impaired below knee. 
A sensory nerve conduction study showed no 
response and low amplitude of sensory nerve action 
potentials at both upper and lower extremities. A 
motor nerve conduction study showed slow conduction 
velocity, no response and low amplitudes of compound 
muscle action potential at both upper and lower 
extremities. On needle electromyography, positive 
sharp waves were observed in the both paraspinal 
muscles, both upper and lower extremities.
We diagnosed her with peripheral sensory motor 
polyneuropathy accompanying axonal involvements 
at both upper and lower extremities, combined with 
carpal tunnel syndrome. According to these findings, 
we suspected FAP and referred her for genetic 
evaluation. Non-Val30Met type FAP with Asp38Ala 
mutation was confirmed (Fig. 2), and same Asp38Ala 
Fig. 1.	Congo	red	stained	specimen	of	cardiac	muscle.	Amyloid	is	
presented	as	amorphous	whitish	materials	(arrow)	under	 light	
microscopy(×200).
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mutation was found in her brother.
Discussion
Amyloid can infiltrate to organ, vessel, cardiac 
muscles and connective tissues. If amyloid infiltrate to 
peripheral nervous system, it shows polyneuropathy 
symptoms.7 FAP’s symptoms usually start with 
discomfort in the feet, including numbness and pain. 
A few months after onset, sensory loss has progressed 
above the ankle level and motor deficits develop in 
the feet and lower legs as well. During the following 
months and years, the sensory deficit gradually extends 
to the thighs and then to the upper extremities. 
The motor deficits also follow a length-dependent 
progression, and walking without an aid is getting 
difficult.2
FAP, caused by deposit of mutated TTR, was classified 
into two types, type I (portuguese) and II (Indiana/
swiss) according to the geographical distribution 
and clinical signs. However, recent genetic analysis 
elucidated that type I is mostly caused by Val30Met 
mutation, and type II is caused by relatively rare 
mutations such as His58, Ser84, Asp70 of non-Val30Met 
type. As more mutations were found by genetic 
analysis, it was known that phenotypes are correlated 
with genotypes. Val30Met type FAP, previously 
known as type I, shows autonomic dysfunction and 
polyneuropathy from the beginning, but non-Val30Met 
type FAP shows various clinical signs and symptoms 
according to kind of genetic mutation.7
Non-Val30Met type FAP caused by Asp38Ala substitu-
tion has been reported rarely and only 8 cases were 
reported in Korea.8-10 They were all male patients and 
accompanied with autonomic dysfunctions without 
exception such as orthostatic hypotension, diarrhea, 
impotence, and urinary incontinence. Three female 
patients with Asp38Ala substitution type FAP were 
reported in Japan and all of them suffered from 
autonomic dysfunctions such as dizziness, constipation 
and diarrhea.11-13 On the contrary, this patient, the first 
female case of Asp38Ala substitution type FAP reported 
in Korea, experienced relatively early-onset cardio-
myopathy without autonomic symptoms. However, 
she had common clinical features with previously 
reported male patients; cardiac involvement, and 
electrodiagnostic abnormalities showing sensory motor 
polyneuropathy or other compressive focal neuropathy. 
Although autonomic dysfunctions are known to be 
less in non-Val30Met type FAP compared to Val30Met 
type FAP, all previously reported cases suffered from 
autonomic symptoms whether they were male or 
female. It was unclear whether this case is exceptional 
or ethnic difference affected the phenotypes. Further 
collection of Korean female cases may determine 
whether ethnicity may affect the clinical characteristics 
of Asp38Ala substitution type FAP.
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